Patent SG-11201809751X-A (SG)
Title: Egfr inhibitor compounds
Inventor: BUNKER KEVIN
IPC: C07D403/14
Filed: 2017-05-24
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 November 2017 (30.11.2017) iii 1111111111111111111111111111111111111111111111111111110111111111111111111111111111111111 (10) International Publication Number WO 2017/205459 Al WIPO I PCT (51) International Patent Classification: CO7D 403/14 (2006.01) A61K 31/404 (2006.01) CO7D 209/04 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2017/034163 (22) International Filing Date: 24 May 2017 (24.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/342,141 26 May 2016 (26.05.2016) US (71) Applicant: KALYRA PHARMACEUTICALS, INC. [US/US]; 10835 Road To The Cure, Suite 205, San Diego, CA 92121 (US). (72) Inventors: BUNKER, Kevin, Duane; 10835 Road To The Cure, Suite 205, San Diego, CA 92121 (US). HUANG, Peter, Qinhua; 10835 Road To The Cure, Suite 205, San Diego, CA 92121 (US). ABRAHAM, Sunny; 10835 Road To The Cure, Suite 205, San Diego, CA 92121 (US). PINCHMAN, Joseph, Robert; 10835 Road To The Cure, Suite 205, San Diego, CA 92121 (US). HOPKINS, Chad, Daniel; 10835 Road To The Cure, Suite 205, San Diego, CA 92121 (US). SLEE, Deborah, Helen; 10835 Road To The Cure, Suite 205, Sab Diego, CA 92121 (US). (74) Agent: MILLIER, Kimberely, J.; Knobbe, Martens, Ol- son & Bear, LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. — (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 1-1 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 71' O TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 2 I (3)) N (54) Title: EGFR INHIBITOR COMPOUNDS 0 (57) : Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods \" of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.